Pembrolizumab (pembro) 1 chemotherapy (chemo) in metastatic squamous NSCLC: Final analysis and progression after the next line of therapy (PFS2) in KEYNOTE-407
dc.authorid | Cicin, Irfan/0000-0002-7584-3868 | |
dc.authorid | SOTO PARRA, HECTOR J/0000-0001-7966-4472 | |
dc.authorid | SOTO PARRA, HECTOR J/0000-0001-7966-4472 | |
dc.authorwosid | Paz-Ares, Luis/AAH-2750-2019 | |
dc.authorwosid | Cicin, Irfan/AAQ-5575-2020 | |
dc.authorwosid | SOTO PARRA, HECTOR J/ABC-6273-2021 | |
dc.authorwosid | SOTO PARRA, HECTOR J/IZE-2180-2023 | |
dc.contributor.author | Paz-Ares, L. | |
dc.contributor.author | Vicente, D. | |
dc.contributor.author | Tafreshi, A. | |
dc.contributor.author | Robinson, A. | |
dc.contributor.author | Soto Parra, H. | |
dc.contributor.author | Mazieres, J. | |
dc.contributor.author | Hermes, B. | |
dc.date.accessioned | 2024-06-12T11:24:06Z | |
dc.date.available | 2024-06-12T11:24:06Z | |
dc.date.issued | 2019 | |
dc.department | Trakya Üniversitesi | en_US |
dc.description | 44th Congress of the European-Society-for-Medical-Oncology (ESMO) -- SEP 27-OCT 01, 2019 -- Barcelona, SPAIN | en_US |
dc.description.abstract | [Abstract Not Available] | en_US |
dc.description.sponsorship | European Soc Med Oncol,Japanese Soc Med Oncol | en_US |
dc.description.sponsorship | Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA | en_US |
dc.description.sponsorship | Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. | en_US |
dc.identifier.issn | 0923-7534 | |
dc.identifier.issn | 1569-8041 | |
dc.identifier.uri | https://hdl.handle.net/20.500.14551/26799 | |
dc.identifier.volume | 30 | en_US |
dc.identifier.wos | WOS:000491295500206 | en_US |
dc.identifier.wosquality | Q1 | en_US |
dc.indekslendigikaynak | Web of Science | en_US |
dc.language.iso | en | en_US |
dc.publisher | Oxford Univ Press | en_US |
dc.relation.ispartof | Annals Of Oncology | en_US |
dc.relation.publicationcategory | Konferans Öğesi - Uluslararası - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | [No Keywords] | en_US |
dc.title | Pembrolizumab (pembro) 1 chemotherapy (chemo) in metastatic squamous NSCLC: Final analysis and progression after the next line of therapy (PFS2) in KEYNOTE-407 | en_US |
dc.type | Conference Object | en_US |